Study terminated for strategic business reasons

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2).

Participation in the study will last about 13 months.

Inclusion Criteria:

• Have a body mass index (BMI) within the range of 22 to 25 kilograms per square meter (kg/m2)
• Have had a stable body weight for 3 months prior to screening

Exclusion Criteria:

• Have type 1 diabetes, latent autoimmune diabetes in adults, or a history of ketoacidosis or hyperosmolar coma

• Have:

  • type 2 diabetes and on antidiabetic therapy (except type 2 diabetes being managed with diet and/or stable dose of metformin)
  • rare forms of diabetes mellitus, or
  • hemoglobin A1c (HbA1c) >8%

• Have poorly controlled hypertension

• Have any of the following cardiovascular conditions within 12 months prior to screening:

  • acute myocardial infarction
  • stroke
  • unstable angina, or
  • hospitalization due to congestive heart failure.

• Have a history of New York Heart Association Functional Classification III or IV congestive heart failure

• Have signs and symptoms of liver disease

• Have a history of pancreatitis

• Have taken medications or alternative remedies for weight loss or weight gain within 3 months prior to screening

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.